-- written by Max Ehrmann in the 1920s --
Not "Found in Old St. Paul's Church"! -
Go placidly amid the noise and the haste,
and remember what peace there may be in silence.
As far as possible, without surrender,
be on good terms with all persons.
Speak your truth quietly and clearly;
and listen to others,
even to the dull and the ignorant;
they too have their story.
Avoid loud and aggressive persons;
they are vexatious to the spirit.
If you compare yourself with others,
you may become vain or bitter,
for always there will be greater and lesser persons than yourself.
Enjoy your achievements as well as your plans.
Keep interested in your own career, however humble;
it is a real possession in the changing fortunes of time.
Exercise caution in your business affairs,
for the world is full of trickery.
But let this not blind you to what virtue there is;
many persons strive for high ideals,
and everywhere life is full of heroism.
Be yourself. Especially do not feign affection.
Neither be cynical about love,
for in the face of all aridity and disenchantment,
it is as perennial as the grass.
Take kindly the counsel of the years,
gracefully surrendering the things of youth.
Nurture strength of spirit to shield you in sudden misfortune.
But do not distress yourself with dark imaginings.
Many fears are born of fatigue and loneliness.
Beyond a wholesome discipline,
be gentle with yourself.
You are a child of the universe
no less than the trees and the stars;
you have a right to be here.
And whether or not it is clear to you,
no doubt the universe is unfolding as it should.
Therefore be at peace with God,
whatever you conceive Him to be.
And whatever your labors and aspirations,
in the noisy confusion of life,
keep peace in your soul.
With all its sham, drudgery, and broken dreams,
it is still a beautiful world.
Be cheerful. Strive to be happy.
Thursday, August 12, 2010
Dr.Simka from Poland
Letter from Dr. Simka regarding restenosis
Letter from Dr. Simka to Esta, a Canadian liberated MSer
Here is a reply, posted on thisisms.com to an inquiry from a Canadian lady who was worried that she may have restenosed. It answers quite a few other questions people may have, as well:
Dr.Simka states:
I will give you some details on our current policy, and also on our findings coming from gathered data. perhaps, you can post this information on thisms.com. since many patients are looking at this forum.
Our main goal of diagnostic procedures is to find all significant (i.e. impairing the outflow) venous lesions. Consequently, we perform Doppler sonography and MR venography as screening tests. Theoretically, both of these examinations are not necessary, but in some patients (~10%) they are very important (anatomical variants, borderline pathology, unoperable lesions).
Doppler sonography and MRV are only screening tests, i.e. (they reveal that there is a pathology and in most of the cases they predict were the pathology is situated). But they are not 100% accurate. Intraoperative venography is far more reliable, but even this test is not perfect. So a combination of Doppler+ MRV + intraoperative venography is better. Now, we are thinking about also applying IVUS (intravenous ultrasonography), but it will substantially increase the cost, so most likely we will use it only in selected cases.
Regarding the treatment, we opt for the most safe and the most efficient treatment, which of course is not possible, since those two parameters don't meet it every case. Balloon angioplasty has already been demonstrated to be very safe in a short period of time, and most likely safe in long period of time and is also nearly perfect. But balloon angioplasty is not very efficacious.
In some cases it doesn't work at all, in others there are late restenoses. The short-term efficacy of an alternative treatment – (stenting) is much higher. But long-term efficacy (risk of late occlusion) is not known. Although an occluded stent can be opened but possibly not in every case. And of course there are known early complications related to stents, namely the migration, that excludes some anatomic variants from stenting (at least using currently available stents). There is also possible the open repair of the vein, but risk and efficacy of such procedures are not known. Thus, all treatment modalities should be regarded as experimental, with still unknown efficacy and safety.
The doctors always try to balance the risk and the efficacy factors, but the best solution is not always possible and is not always chosen (importantly, we don't have data on long term consequences of ballooning or stenting).
Now, what about impact of the treatment for CCSVI on clinical course of MS?.
Our data indicates that the things are far more complicated than it might be expected.
1. CCSVI is not the only cause for MS; most likely, MS = CCSVI + some (probably more than one) other factors
2. Consequently, treating CCSVI does not mean that MS is gone. Most of the patients experience good and bad days following surgery and importantly, during infection, stress, etc. The symptoms usually subside and resolve. but the symptoms also return in a case of restenosis.
3. Treatment of CCSVI does not guarantee improvement. There were some patients (not many) who experienced worsening.
Most of those patients presented with severely narrowed veins that could not be sufficiently managed with ballooning or stenting, but there were also cases with "perfectly" done surgery. So, a patient can improve after surgery (a majority, especially relapsing remitting patients), but no improvement or even worsening is also possible. A reoperation can improve the symptoms in the latter two groups, but again, not in all cases.
4. Probably, surgery for CCSVI + pharmaceutical treatment will improve outcomes. Try to continue your neurological medication if it was working before surgery.
5. Many patients who suffered from transient worsening of symptoms, improved after inclined bed therapy.
You can try it, even if not efficient, at least it is 100% safe
6. Postoperative Doppler examination is sometimes puzzling. In most of the patients the flow just after the surgery is still pathologic. Therefore we don't perform it after operation (we don't want to stress the patients). Even after some days there are still flow abnormalities, especially after ballooning. So, we think that patient should look at his/her symptoms first.
And, most importantly,the current situation when patients must travel thousands of miles to have the treatment is neither normal nor is it safe.
At the moment healthcare systems seem to overregulated.
It must be changed, especially the cooperation with the neurological community and big universities with access to big public money is pivotal.
Surgery is not the only solution, it must be augmented by something else.
Sincerely
Dr.M.Simka
Letter from Dr. Simka to Esta, a Canadian liberated MSer
Here is a reply, posted on thisisms.com to an inquiry from a Canadian lady who was worried that she may have restenosed. It answers quite a few other questions people may have, as well:
Dr.Simka states:
I will give you some details on our current policy, and also on our findings coming from gathered data. perhaps, you can post this information on thisms.com. since many patients are looking at this forum.
Our main goal of diagnostic procedures is to find all significant (i.e. impairing the outflow) venous lesions. Consequently, we perform Doppler sonography and MR venography as screening tests. Theoretically, both of these examinations are not necessary, but in some patients (~10%) they are very important (anatomical variants, borderline pathology, unoperable lesions).
Doppler sonography and MRV are only screening tests, i.e. (they reveal that there is a pathology and in most of the cases they predict were the pathology is situated). But they are not 100% accurate. Intraoperative venography is far more reliable, but even this test is not perfect. So a combination of Doppler+ MRV + intraoperative venography is better. Now, we are thinking about also applying IVUS (intravenous ultrasonography), but it will substantially increase the cost, so most likely we will use it only in selected cases.
Regarding the treatment, we opt for the most safe and the most efficient treatment, which of course is not possible, since those two parameters don't meet it every case. Balloon angioplasty has already been demonstrated to be very safe in a short period of time, and most likely safe in long period of time and is also nearly perfect. But balloon angioplasty is not very efficacious.
In some cases it doesn't work at all, in others there are late restenoses. The short-term efficacy of an alternative treatment – (stenting) is much higher. But long-term efficacy (risk of late occlusion) is not known. Although an occluded stent can be opened but possibly not in every case. And of course there are known early complications related to stents, namely the migration, that excludes some anatomic variants from stenting (at least using currently available stents). There is also possible the open repair of the vein, but risk and efficacy of such procedures are not known. Thus, all treatment modalities should be regarded as experimental, with still unknown efficacy and safety.
The doctors always try to balance the risk and the efficacy factors, but the best solution is not always possible and is not always chosen (importantly, we don't have data on long term consequences of ballooning or stenting).
Now, what about impact of the treatment for CCSVI on clinical course of MS?.
Our data indicates that the things are far more complicated than it might be expected.
1. CCSVI is not the only cause for MS; most likely, MS = CCSVI + some (probably more than one) other factors
2. Consequently, treating CCSVI does not mean that MS is gone. Most of the patients experience good and bad days following surgery and importantly, during infection, stress, etc. The symptoms usually subside and resolve. but the symptoms also return in a case of restenosis.
3. Treatment of CCSVI does not guarantee improvement. There were some patients (not many) who experienced worsening.
Most of those patients presented with severely narrowed veins that could not be sufficiently managed with ballooning or stenting, but there were also cases with "perfectly" done surgery. So, a patient can improve after surgery (a majority, especially relapsing remitting patients), but no improvement or even worsening is also possible. A reoperation can improve the symptoms in the latter two groups, but again, not in all cases.
4. Probably, surgery for CCSVI + pharmaceutical treatment will improve outcomes. Try to continue your neurological medication if it was working before surgery.
5. Many patients who suffered from transient worsening of symptoms, improved after inclined bed therapy.
You can try it, even if not efficient, at least it is 100% safe
6. Postoperative Doppler examination is sometimes puzzling. In most of the patients the flow just after the surgery is still pathologic. Therefore we don't perform it after operation (we don't want to stress the patients). Even after some days there are still flow abnormalities, especially after ballooning. So, we think that patient should look at his/her symptoms first.
And, most importantly,the current situation when patients must travel thousands of miles to have the treatment is neither normal nor is it safe.
At the moment healthcare systems seem to overregulated.
It must be changed, especially the cooperation with the neurological community and big universities with access to big public money is pivotal.
Surgery is not the only solution, it must be augmented by something else.
Sincerely
Dr.M.Simka
Dr. Salvatore Sclafani
Dr Sclafani's response to the German and Swedish Study
11 August, 2010
It is regretful that Drs. Doepp and co-authors' attempt to reproduce Professor Zamboni's discovery of a link between multiple sclerosis and disturbance of the outflow veins of the brain and spine has been unsuccessful.
It is particularly unfortunate that the authors' misunderstanding of Dr. Zamboni's publications about this subject have led to their conclusions that "No cerebrocervical venous congestion in patients with multiple sclerosis" exists
The authors mis-state several of the criteria for a positive ultrasound examination. They state that reflux must be present in both internal jugular veins or both vertebral veins. This is not accurate. Reflux in any one of these veins was considered a positive criteria by Zamboni.
It appears to me that Dr Doepp and colleagues have tried to elicit reflux by testing for incompetent valves in the lower jugular vein. Incompetent valves result in reversal of blood flow from the heart back up into the jugular veins. They used the Valsalva maneurer, a technique to increase pressure in the chest that reverses blood flow. However, Zamboni explicitly states that one should assess flow "never in (by) a forced condition such as the Valsalva manoeuvre."
That the authors' attempts were unsuccessful is not surprising. The ultrasound examination used by Zamboni is a simple one but the description of the technique has not been fully elaborated in his papers. Thus performance of the ultrasound by some investigators is often at variance and this may lead to differences of results. At my own institution, we were surprised that non-invasive testing by ultrasound did not correlate with the very obvious obstructive phenomena seen on catheter venography, which remains the Gold Standard of assessing veins. We also had difficulty identifying CCSVI on ultrasound, initially using the Valsalva maneuver during out testing. In fact we were able to find an obstruction in only one patient of twenty. It was only after being shown how to correctly perform this simple screening test by the Zamboni team during a visit to Ferrara, that we have become facile in detecting these abnormalities. It is clear that there is a learning curve to the use of this technique.
Nor does this paper refute the concept of CCSVI. Doppler ultrasound is only a screening test for CCSVI. When Doppler shows signs of CCSVI, the gold standard test of catheter venography is indicated to detect the sites of potential obstruction.
Doppler is not the definitive test of CCSVI because it cannot assess the azygous vein, an important contributor to cerebrspinal venous outflow resistance. Catheter venographies routinely show evidence of outflow obstructions. Sluggish flow, reversal of flow, extensive collateral veins, strictures, duplications, reversed valves, thickened incompletely opening valves and misplaced valves are among the many abnormalities seen in MS patients that we never see in patients without MS.
The paper by Sundstrom and coauthors similarly rejected the CCSVI hypothesis by performing MR venograms and flow quantification in the neck. MR venography is suboptimal as a screening test because it underestimates and overestimates stenoses quite regularly.
One can see from their illustrations two MRV images. It is noteworthy that neither image shows the portion of the jugular vein where lesions causing flow resistance are usually found: behind the clavicle as the vessel enters the chest. Both images show considerable collateral vasculature suggestive of CCSVI. Moreover the image on the right on page 258 purports to show a stenosis with an arrow. It is well known that most of the narrowings referred to by the white arrow are a common transient, non-stenotic narrowing caused by a true narrowing below the clavicle. Catheter venography shows abnormalities that cannot be detected by MRV.
I was struck by the rapidity of publication of both articles. Surprising! Both papers were accepted within six weeks. I have never had such rapid decision, editing and publication of any of my more than 120 publications.
This debate is going to be a challenging one. One side wants randomized prospective trials to prove efficacy.
However while many proceduralists have noted sometimes impressive gains for patients, these proceduralists need to evaluate nuances of techniques before consensus can be built regarding the best approach to therapy. Only then can intelligent, carefully designed randomized prospective trials begin. Some who commonly perform randomized trials will try to reduce the work of those who will try to develop the best practices because they are not randomized. However, in my view this is a necessary initial step toward the final trials.
http://www.facebook.com/notes/ccsvi-transverse-myelitis/dr-sclafanis-view-on-german-and-swedish-studies-on-ccsvi-posted-in-thisisms-foru/149907845020797
11 August, 2010
It is regretful that Drs. Doepp and co-authors' attempt to reproduce Professor Zamboni's discovery of a link between multiple sclerosis and disturbance of the outflow veins of the brain and spine has been unsuccessful.
It is particularly unfortunate that the authors' misunderstanding of Dr. Zamboni's publications about this subject have led to their conclusions that "No cerebrocervical venous congestion in patients with multiple sclerosis" exists
The authors mis-state several of the criteria for a positive ultrasound examination. They state that reflux must be present in both internal jugular veins or both vertebral veins. This is not accurate. Reflux in any one of these veins was considered a positive criteria by Zamboni.
It appears to me that Dr Doepp and colleagues have tried to elicit reflux by testing for incompetent valves in the lower jugular vein. Incompetent valves result in reversal of blood flow from the heart back up into the jugular veins. They used the Valsalva maneurer, a technique to increase pressure in the chest that reverses blood flow. However, Zamboni explicitly states that one should assess flow "never in (by) a forced condition such as the Valsalva manoeuvre."
That the authors' attempts were unsuccessful is not surprising. The ultrasound examination used by Zamboni is a simple one but the description of the technique has not been fully elaborated in his papers. Thus performance of the ultrasound by some investigators is often at variance and this may lead to differences of results. At my own institution, we were surprised that non-invasive testing by ultrasound did not correlate with the very obvious obstructive phenomena seen on catheter venography, which remains the Gold Standard of assessing veins. We also had difficulty identifying CCSVI on ultrasound, initially using the Valsalva maneuver during out testing. In fact we were able to find an obstruction in only one patient of twenty. It was only after being shown how to correctly perform this simple screening test by the Zamboni team during a visit to Ferrara, that we have become facile in detecting these abnormalities. It is clear that there is a learning curve to the use of this technique.
Nor does this paper refute the concept of CCSVI. Doppler ultrasound is only a screening test for CCSVI. When Doppler shows signs of CCSVI, the gold standard test of catheter venography is indicated to detect the sites of potential obstruction.
Doppler is not the definitive test of CCSVI because it cannot assess the azygous vein, an important contributor to cerebrspinal venous outflow resistance. Catheter venographies routinely show evidence of outflow obstructions. Sluggish flow, reversal of flow, extensive collateral veins, strictures, duplications, reversed valves, thickened incompletely opening valves and misplaced valves are among the many abnormalities seen in MS patients that we never see in patients without MS.
The paper by Sundstrom and coauthors similarly rejected the CCSVI hypothesis by performing MR venograms and flow quantification in the neck. MR venography is suboptimal as a screening test because it underestimates and overestimates stenoses quite regularly.
One can see from their illustrations two MRV images. It is noteworthy that neither image shows the portion of the jugular vein where lesions causing flow resistance are usually found: behind the clavicle as the vessel enters the chest. Both images show considerable collateral vasculature suggestive of CCSVI. Moreover the image on the right on page 258 purports to show a stenosis with an arrow. It is well known that most of the narrowings referred to by the white arrow are a common transient, non-stenotic narrowing caused by a true narrowing below the clavicle. Catheter venography shows abnormalities that cannot be detected by MRV.
I was struck by the rapidity of publication of both articles. Surprising! Both papers were accepted within six weeks. I have never had such rapid decision, editing and publication of any of my more than 120 publications.
This debate is going to be a challenging one. One side wants randomized prospective trials to prove efficacy.
However while many proceduralists have noted sometimes impressive gains for patients, these proceduralists need to evaluate nuances of techniques before consensus can be built regarding the best approach to therapy. Only then can intelligent, carefully designed randomized prospective trials begin. Some who commonly perform randomized trials will try to reduce the work of those who will try to develop the best practices because they are not randomized. However, in my view this is a necessary initial step toward the final trials.
http://www.facebook.com/notes/ccsvi-transverse-myelitis/dr-sclafanis-view-on-german-and-swedish-studies-on-ccsvi-posted-in-thisisms-foru/149907845020797
Ruth Ann Marrie Vascular Comorbiity and Progession of MS
Ruth Ann Marrie Discusses Vascular Comorbidity and Rapid Disability Progression in MS
March 22, 2010
Ruth Ann Marrie, MD, PhD, Director of the Multiple Sclerosis Clinic, and Assistant Professor of Medicine and Community Health Sciences at the University of Manitoba, talks about vascular comorbidities and risk factors and their effect on the progression of multiple sclerosis. Her paper, "Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis," was published recently in Neurology®' (2009;72:117-124). She spoke with José G. Merino, MD, MPhil, Science Editor of AAN.com.
AAN.com: Please describe the methodology of your study.
Marrie: We were interested in the effect of vascular comorbidities on the progression of disability in patients with multiple sclerosis (MS). In October 2006, we asked participants in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry to report their comorbidities, including the year of diagnosis. We linked this information to demographic and clinical information reported by participants upon enrollment in the Registry and in their semi-annual updates. We grouped diabetes, hypertension, heart disease, hyperlipidemia, and peripheral vascular disease together as vascular comorbidities.
We considered two scenarios. In the first, we examined whether vascular comorbidity at diagnosis affects subsequent progression of ambulatory disability. For this analysis, we compared participants who reported one or more vascular comorbidities at the time of their MS diagnosis to those who never developed one. This scenario was meant to reflect the situation faced by a clinician treating a patient with newly diagnosed MS. In the second scenario, we examined whether the development of vascular comorbidity at any point in the disease course affected the time between symptom onset and the same disability outcomes, using Cox proportional hazards models with time dependent covariates. We found that vascular comorbidities adversely affected the course of the disease.
AAN.com: In your study, what vascular comorbidities or risk factors were the most closely associated with the progression of disability in patients with MS?
Marrie: The effects of all of the vascular comorbidities studied were quite similar, except for heart disease, for which there was no significant effect.
AAN.com: How did the timing of the appearance of the vascular comorbidities (at onset versus later in the course of the disease) alter the association between these conditions and disease progression?
Marrie: The association between the vascular comorbidities and disability progression was similar regardless of whether the comorbidity was present at MS onset, diagnosis, or later in the disease course. Study participants with vascular comorbidities had more rapid disability progression than those without vascular comorbidities.
AAN.com: Do vascular comorbidities affect disease progression among patients with MS by promoting and potentiating cerebrovascular disease?
Marrie: We did not examine cerebrovascular disease in this study, though this is an important issue—and a potential explanation for our findings. The question requires further study.
AAN.com: What are possible explanations for the observed association between vascular risk factors and disease progression in MS patients?
Marrie: Our study did not examine the mechanisms by which vascular comorbidities affected disease progression, but altered blood vessel structure and function, increased susceptibility to oxidative stress, or increased peripheral inflammation are all considerations.
AAN.com: The presence of vascular comorbidities and risk factors has been associated with the development of cognitive impairment, including Alzheimer's disease, on elderly patients. Did you find any effect of the presence of vascular risk factors on cognition in patients with MS?
Marrie: In this study we focused on the impact of vascular risk factors on gait disability, and did not examine other aspects of disability such as vision, cognition, or hand function. To my knowledge, other studies examining the impact of comorbidities on MS also have focused on gait disability, not cognitive disability.
AAN.com: For your outcome assessment you used the Patient Determined Disease Steps scale. What are the features of this scale? How does it differ from the Expanded Disability Status Scale (EDSS)?
Marrie: Patient Determined Disease Steps is a validated self-report measure that assesses gait disability. It is scored from 0 (no disability) to 8 (bedbound). A score of 3 represents early gait disability without needing an assistive device and approximates an EDSS score of 4.0 to 4.5; and scores of 4, 5, and 6 represent EDSS scores of 6 (uses unilateral assistive device to walk) to 6.5 (uses bilateral assistance to walk). It correlates well with a physician scored EDSS (r = 0.94) and can be completed easily by patients.
AAN.com: What is the NARCOMS Registry?
Marrie: The NARCOMS Registry is a project of the Consortium of MS Centers; it is a large self-report registry for persons with MS. Participants voluntarily provide sociodemographic information and clinical information about their MS at enrollment and semi-annually thereafter. Clinical information provided includes disability and treatment status. The registry includes more than 30,000 unique participants, more than 15,000 of whom are in active status.
AAN.com: What is the main message from your findings for general neurologists?
Marrie: Our findings suggest that vascular comorbidity at any point in the course of MS is associated with an increased risk of disability progression. This raises the question of whether treating these comorbidities more aggressively could improve outcomes in MS.
Author Disclosure
Dr. Merino performed a one-time consultation with staff from Bell, Falla and Associates.
March 22, 2010
Ruth Ann Marrie, MD, PhD, Director of the Multiple Sclerosis Clinic, and Assistant Professor of Medicine and Community Health Sciences at the University of Manitoba, talks about vascular comorbidities and risk factors and their effect on the progression of multiple sclerosis. Her paper, "Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis," was published recently in Neurology®' (2009;72:117-124). She spoke with José G. Merino, MD, MPhil, Science Editor of AAN.com.
AAN.com: Please describe the methodology of your study.
Marrie: We were interested in the effect of vascular comorbidities on the progression of disability in patients with multiple sclerosis (MS). In October 2006, we asked participants in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry to report their comorbidities, including the year of diagnosis. We linked this information to demographic and clinical information reported by participants upon enrollment in the Registry and in their semi-annual updates. We grouped diabetes, hypertension, heart disease, hyperlipidemia, and peripheral vascular disease together as vascular comorbidities.
We considered two scenarios. In the first, we examined whether vascular comorbidity at diagnosis affects subsequent progression of ambulatory disability. For this analysis, we compared participants who reported one or more vascular comorbidities at the time of their MS diagnosis to those who never developed one. This scenario was meant to reflect the situation faced by a clinician treating a patient with newly diagnosed MS. In the second scenario, we examined whether the development of vascular comorbidity at any point in the disease course affected the time between symptom onset and the same disability outcomes, using Cox proportional hazards models with time dependent covariates. We found that vascular comorbidities adversely affected the course of the disease.
AAN.com: In your study, what vascular comorbidities or risk factors were the most closely associated with the progression of disability in patients with MS?
Marrie: The effects of all of the vascular comorbidities studied were quite similar, except for heart disease, for which there was no significant effect.
AAN.com: How did the timing of the appearance of the vascular comorbidities (at onset versus later in the course of the disease) alter the association between these conditions and disease progression?
Marrie: The association between the vascular comorbidities and disability progression was similar regardless of whether the comorbidity was present at MS onset, diagnosis, or later in the disease course. Study participants with vascular comorbidities had more rapid disability progression than those without vascular comorbidities.
AAN.com: Do vascular comorbidities affect disease progression among patients with MS by promoting and potentiating cerebrovascular disease?
Marrie: We did not examine cerebrovascular disease in this study, though this is an important issue—and a potential explanation for our findings. The question requires further study.
AAN.com: What are possible explanations for the observed association between vascular risk factors and disease progression in MS patients?
Marrie: Our study did not examine the mechanisms by which vascular comorbidities affected disease progression, but altered blood vessel structure and function, increased susceptibility to oxidative stress, or increased peripheral inflammation are all considerations.
AAN.com: The presence of vascular comorbidities and risk factors has been associated with the development of cognitive impairment, including Alzheimer's disease, on elderly patients. Did you find any effect of the presence of vascular risk factors on cognition in patients with MS?
Marrie: In this study we focused on the impact of vascular risk factors on gait disability, and did not examine other aspects of disability such as vision, cognition, or hand function. To my knowledge, other studies examining the impact of comorbidities on MS also have focused on gait disability, not cognitive disability.
AAN.com: For your outcome assessment you used the Patient Determined Disease Steps scale. What are the features of this scale? How does it differ from the Expanded Disability Status Scale (EDSS)?
Marrie: Patient Determined Disease Steps is a validated self-report measure that assesses gait disability. It is scored from 0 (no disability) to 8 (bedbound). A score of 3 represents early gait disability without needing an assistive device and approximates an EDSS score of 4.0 to 4.5; and scores of 4, 5, and 6 represent EDSS scores of 6 (uses unilateral assistive device to walk) to 6.5 (uses bilateral assistance to walk). It correlates well with a physician scored EDSS (r = 0.94) and can be completed easily by patients.
AAN.com: What is the NARCOMS Registry?
Marrie: The NARCOMS Registry is a project of the Consortium of MS Centers; it is a large self-report registry for persons with MS. Participants voluntarily provide sociodemographic information and clinical information about their MS at enrollment and semi-annually thereafter. Clinical information provided includes disability and treatment status. The registry includes more than 30,000 unique participants, more than 15,000 of whom are in active status.
AAN.com: What is the main message from your findings for general neurologists?
Marrie: Our findings suggest that vascular comorbidity at any point in the course of MS is associated with an increased risk of disability progression. This raises the question of whether treating these comorbidities more aggressively could improve outcomes in MS.
Author Disclosure
Dr. Merino performed a one-time consultation with staff from Bell, Falla and Associates.
Wednesday, August 11, 2010
Tuesday, August 10, 2010
Liberation Treatment: Letter to the Editor
Liberation Treatment Should Be a Non-Issue
Is dying better than angioplasty? Is progressively getting more disabled better than angioplasty? Is going blind better than angioplasty? Is lying in bed missing your kids growing up better than angioplasty?
We all know the choices we would make given these alternatives. Here in “democratic” Canada these choices have been taken away from people who have Multiple Sclerosis. Our federal and provincial governments have prevented doctors who want to help people from fulfilling the oath that they took when they became doctors.
Angioplasty is a well known, standard medical treatment. It is not a drug and clinical studies are not needed to prove that it is safe. The approximately 1,000 successful liberation treatments done to date around the world should be enough to encourage the Canadian health-care system to allow the treatment as an option to patients.
The arguments against the Liberation Treatment are: “it hasn’t been proven to help people with MS”; “not all the clinics are using the Zamboni method”; “Stents are dangerous in veins”; “we only have anecdotal evidence of the results”; “we don’t know the long term impact”; “the veins can re-stenos”; “not everyone who has MS has CCSVI”.
If we don’t do the Liberation Treatment and track the results we will never be able to prove anything. There is a global community of doctors that are performing the procedure, sharing their experiences and learning and improving together. We are falling way behind because we are not even in the game! Thousands of dollars are leaving Canada because we refuse to listen. The MS Society is not listening to its members; the provincial and federal governments are not listening to their constituents; the health care systems are not listening to their patients. Brad Wall is the first person in power who has stepped forward to say we need to do this.
Pharmaceutical companies control the medical research that is done because they control the money. This procedure does not need pharmaceuticals so there is no money to do the procedure. Or so it would seem! Many people with MS: take drugs that cost over $20,000 a year – paid for by insurance companies and governments; are on disability – paid for by insurance companies and government; see doctors regularly – paid for by governments; have MRI’s – paid for by governments; don’t work and therefore don’t pay income tax and may be on social assistance – paid for by governments.
If we could change this scenario in just a few of the thousands of Canadians with MS we could easily pay to do the procedure, track the results and become part of the global medical community that is sharing information. We don’t need to do everything ourselves. We don’t need to prove everything ourselves. We could start with the many Canadians that have already had the treatment. Follow them, collect the data about them.
What we need to move this forward is:
•Introduce compassionate legislation so that anyone can get medical treatment for compassionate reasons
•Allow the Canadian doctors who’ve already been trained to start doing the Liberation Treatment
•Allow other interested vascular specialists and radiologists to get the training that is needed to ensure they know how to test for CCSVI and do the angioplasty
•Set up a tracking system to gather data about everyone who is tested and treated.
•Include open minded neurologists to follow their patients before and after treatment
•Connect with the global community of doctors to share information
If governments really feel that we can’t afford to do this, call it an elective procedure and charge a fee for having it done. At least the money would stay in Canada and benefit Canadians.
Most importantly, allow us to make a choice about our life. Don’t make the choice for us because you’re scared, sceptical, or think you know best.
I’ve had the procedure and I’m improving for the first time in over 14 years!!
Verna Mang
Is dying better than angioplasty? Is progressively getting more disabled better than angioplasty? Is going blind better than angioplasty? Is lying in bed missing your kids growing up better than angioplasty?
We all know the choices we would make given these alternatives. Here in “democratic” Canada these choices have been taken away from people who have Multiple Sclerosis. Our federal and provincial governments have prevented doctors who want to help people from fulfilling the oath that they took when they became doctors.
Angioplasty is a well known, standard medical treatment. It is not a drug and clinical studies are not needed to prove that it is safe. The approximately 1,000 successful liberation treatments done to date around the world should be enough to encourage the Canadian health-care system to allow the treatment as an option to patients.
The arguments against the Liberation Treatment are: “it hasn’t been proven to help people with MS”; “not all the clinics are using the Zamboni method”; “Stents are dangerous in veins”; “we only have anecdotal evidence of the results”; “we don’t know the long term impact”; “the veins can re-stenos”; “not everyone who has MS has CCSVI”.
If we don’t do the Liberation Treatment and track the results we will never be able to prove anything. There is a global community of doctors that are performing the procedure, sharing their experiences and learning and improving together. We are falling way behind because we are not even in the game! Thousands of dollars are leaving Canada because we refuse to listen. The MS Society is not listening to its members; the provincial and federal governments are not listening to their constituents; the health care systems are not listening to their patients. Brad Wall is the first person in power who has stepped forward to say we need to do this.
Pharmaceutical companies control the medical research that is done because they control the money. This procedure does not need pharmaceuticals so there is no money to do the procedure. Or so it would seem! Many people with MS: take drugs that cost over $20,000 a year – paid for by insurance companies and governments; are on disability – paid for by insurance companies and government; see doctors regularly – paid for by governments; have MRI’s – paid for by governments; don’t work and therefore don’t pay income tax and may be on social assistance – paid for by governments.
If we could change this scenario in just a few of the thousands of Canadians with MS we could easily pay to do the procedure, track the results and become part of the global medical community that is sharing information. We don’t need to do everything ourselves. We don’t need to prove everything ourselves. We could start with the many Canadians that have already had the treatment. Follow them, collect the data about them.
What we need to move this forward is:
•Introduce compassionate legislation so that anyone can get medical treatment for compassionate reasons
•Allow the Canadian doctors who’ve already been trained to start doing the Liberation Treatment
•Allow other interested vascular specialists and radiologists to get the training that is needed to ensure they know how to test for CCSVI and do the angioplasty
•Set up a tracking system to gather data about everyone who is tested and treated.
•Include open minded neurologists to follow their patients before and after treatment
•Connect with the global community of doctors to share information
If governments really feel that we can’t afford to do this, call it an elective procedure and charge a fee for having it done. At least the money would stay in Canada and benefit Canadians.
Most importantly, allow us to make a choice about our life. Don’t make the choice for us because you’re scared, sceptical, or think you know best.
I’ve had the procedure and I’m improving for the first time in over 14 years!!
Verna Mang
Subscribe to:
Posts (Atom)

